GMED - Globus Medical's Untapped Potential Beyond The NUVA Transaction; Analyst Turns Bullish | Benzinga
Stifel analyst Mathew Blackman upgraded Globus Medical, Inc. (NYSE: GMED) to Buy from Hold, lowering the price target to $61 from $65.
Overall, Blackman believes GMED is arguably the "best-in-class" publicly traded Spine company, underscored by a decade-plus of crisp clinical and commercial execution driving sustained, well-above-market growth and unmatched 30%+ EBITDA margins.
The story has evolved, though, with the NUVA transaction bringing pessimistic sentiment and a discounted valuation, the analyst adds.
The analyst notes that the ...